Sodium alginate
CAS 9005-38-3
Sodium alginate (CAS 9005-38-3) is a pharmaceutical compound with 0 bioactivity targets and 188 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Cross-Reference to Chemicals
Same-CAS substance identity is available in the industrial chemicals vertical.
Sodium alginate is linked to DTXSID0040410 in DSSTox identifiers.
View industrial chemical data →Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| Sodium Alginate | 56446 | SU | MTHSPL |
| SODIUM ALGINATE | 56446 | SU | MTHSPL |
| sodium alginate | 56446 | SU | MTHSPL |
| sodium alginate | 56446 | PIN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Sodium alginate used for in pharmaceutical contexts?
Sodium alginate (CAS 9005-38-3) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Sodium alginate?
Sodium alginate has 188 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Acute graft versus host disease in intestine, Administration site nodule, Amyloid related imaging abnormality-oedema/effusion, Anaemia, Anal incontinence. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Sodium alginate also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Algin with EU status "permitted".
What clinical phase is Sodium alginate in?
No phase 1-4 clinical development badge is rendered for Sodium alginate because the matched compound identifier rows do not contain a max-phase value.